THE DEAL, AT A GLANCE

Link Cell Therapies

4/4 reviewed

Link Cell Therapies

Link develops cell therapies that help immune T cells target cancer cells while sparing healthy tissue.

Link announced its Series A was expanded by $30 million to $90 million.

01What it doesLink develops cell therapies that help immune T cells target cancer cells while sparing healthy tissue.Source-grounded · automated review · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

Link's proprietary logic-gating technology allows…

02Who is involvedJohnson & Johnson led; Samsara, Sheatree, Wing, BMS, Kyowa Kirin and others participated.Source-grounded · automated review · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

Series A financing led by…

03What happenedLink announced its Series A was expanded by $30 million to $90 million.Source-grounded · automated review · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

today announced that it has…

04Why it mattersThe larger round funds cancer therapy trials and development beyond Link's lead kidney cancer program.Interpretation · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

Series A financing upsized from…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

Link Cell Therapies · Financing Record

Explore source-linked visual explanations for Link Cell Therapies. Unsupported claims are withheld while source review continues.

Record 13048 · Recorded date: 2026-09-29